Vertex to acquire Crinetics Pharmaceuticals for $10B; CRNX shares surge 98%

Brett Schafer, The Motley Fool Fri, July 10, 2026 at 12:22 PM PDT | 2 min read

• CRNX: -0.05%
• NVDA: +4.03%
• VRTX: -2.24%

Shares of Crinetics Pharmaceuticals (NASDAQ: CRNX) jumped 98% this week, according to data from S&P Global Market Intelligence. The upstart drugmaker is being acquired by Vertex Pharmaceuticals for $10 billion in cash, less than a year after its first drug was approved by the Food and Drug Administration (FDA).

The stock is now trading just below its acquisition price of $85 and has delivered 300% returns for investors over the past five years. Here's why Crinetics stock was soaring this week and what investors should do now.

An All-Cash Deal for Promising Drugs

Vertex Pharmaceuticals, a large-cap drugmaker, is paying $10 billion to acquire Crinetics and its portfolio of drugs — or $8.8 billion net of cash on the Crinetics balance sheet.

Crinetics has a drug called Palsonify, approved by the FDA in September 2025 and recently approved in the European Union, which is an oral treatment for a condition called Acromegaly. It also has a pipeline of other drugs in clinical trials.

The acquisition is intended to give Vertex a pipeline of potential drugs to diversify away from its dependence on the cystic fibrosis market, which it currently dominates. Management wants to add new pillars to its business focused on rare diseases — an area where Crinetics fits perfectly. Combined, Vertex believes the Crinetics assets have the potential to generate $5 billion in annual revenue.

Should You Buy Crinetics Stock?

After the announcement, Crinetics stock now trades at $83.62, a small percentage below its acquisition price of $85. Investors can continue holding Crinetics stock until they receive cash for their shares, but the implied returns are likely similar to those of holding treasury bonds. There is no compelling reason to keep holding Crinetics shares right now. Take the money and find other opportunities after these massive gains.

Should You Buy Stock in Crinetics Pharmaceuticals Right Now?

Before you buy stock in Crinetics Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now — and Crinetics Pharmaceuticals was not one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004: if you invested $1,000 at the time of our recommendation, you'd have $407,004! Or when Nvidia made this list on April 15, 2005: if you invested $1,000 at the time of our recommendation, you'd have $1,244,599!

Stock Advisor's total average return is 924% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor.